Vitamins lower blood homocysteine levels
- Trial ID
- NCT06772220
- Official Title
- Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease
- Goal
- Vitamins lower blood homocysteine levels
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Oregon Health and Science University
- Study Type
- INTERVENTIONAL
- Enrollment
- 150 participants
- Conditions
- Parkinson&Amp;#39;s Disease
- Interventions
- Folic Acid 1 MG, Vitamin B6 25 MG, Vitamin B12
Plain-Language Summary
The goal is to lower high homocysteine that can rise with levodopa use and may contribute to vascular problems and cognitive decline in people with Parkinson's. The approach gives daily folic acid 1 mg, vitamin B6 25 mg, and vitamin B12 to help the body convert homocysteine into methionine or cysteine, thereby lowering blood homocysteine levels; these supplements are intended to be added to existing levodopa treatment and generally do not reduce levodopa's benefit when used with standard decarboxylase inhibitors like carbidopa. The study is enrolling people ages 40 to 90 with probable Parkinson's who are taking at least 300 mg of levodopa per day, have a MOCA of 15 or higher, adequate kidney function, no uncontrolled high blood pressure, are not using insulin, and can give informed consent.
Locations
- Oregon Health & Science University (OHSU), Portland, Oregon, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Folic Acid 1 MG. The goal is to lower high homocysteine that can rise with levodopa use and may contribute to vascular problems and cognitive decline in people with Parkinson's. The approach gives daily folic acid 1 mg, vitamin B6 25 mg, and vitamin B12 to help the body convert homocysteine into methionine or cysteine, thereby lowering blood homocysteine levels; these supplements are intended to be added to existing levodopa treatment and generally do not reduce levodopa's benefit when used with standard decarboxylase inhibitors like carbidopa. The study is enrolling people ages 40 to 90 with probable Parkinson's who are taking at least 300 mg of levodopa per day, have a MOCA of 15 or higher, adequate kidney function, no uncontrolled high blood pressure, are not using insulin, and can give informed consent.
- Who can participate?
- Participants must be between 40 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 10 months.